Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
Conditions: SARS-CoV-2 Infection; COVID-19 Interventions: Biological: BNT162b2; Other: Placebo; Biological: Seasonal Inactivated Influenza Vaccine Sponsors: Pfizer Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Covid Vaccine | COVID-19 | Influenza | Influenza Vaccine | Pfizer | Research | SARS | Vaccines